{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:50:29Z","timestamp":1785246629924,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Perinatology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.clp.2013.02.005","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T09:44:58Z","timestamp":1369302298000},"page":"297-310","source":"Crossref","is-referenced-by-count":29,"title":["Current and Future Trends in Treatment of Severe Retinopathy of Prematurity"],"prefix":"10.1016","volume":"40","author":[{"given":"David K.","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine Y.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clp.2013.02.005_bib1","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clp.2013.02.005_bib2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archophthalmol.2010.72","article-title":"Final visual acuity results in the early treatment for retinopathy of prematurity study","volume":"128","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"10.1016\/j.clp.2013.02.005_bib3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1001\/archopht.1990.01070120056029","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity one-year outcome: structure and function","volume":"108","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clp.2013.02.005_bib4","first-page":"1","article-title":"Correlation of recognition visual acuity with posterior retinal structure in advanced retinopathy of prematurity","volume":"13","author":"Wallace","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clp.2013.02.005_bib5","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1097\/IAE.0b013e31821dfa6d","article-title":"Macular features from spectral-domain optical coherence tomography as an adjunct to indirect ophthalmoscopy in retinopathy of prematurity","volume":"31","author":"Lee","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.clp.2013.02.005_bib6","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1167\/iovs.08-2584","article-title":"Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture","volume":"49","author":"Smith","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clp.2013.02.005_bib7","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.3109\/14767058.2012.684109","article-title":"Intravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment. A case series","volume":"25","author":"Dani","year":"2012","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.clp.2013.02.005_bib8","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"Suppl","key":"10.1016\/j.clp.2013.02.005_bib9","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":"Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.clp.2013.02.005_bib10","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00417-011-1678-9","article-title":"Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series","volume":"249","author":"Roohipoor","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.clp.2013.02.005_bib11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":"Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan","volume":"118","author":"Wu","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clp.2013.02.005_bib12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.clp.2013.02.005_bib13","doi-asserted-by":"crossref","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","article-title":"Are we there yet? Bevacizumab therapy for\u00a0retinopathy of prematurity","volume":"98","author":"Darlow","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.clp.2013.02.005_bib14","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clp.2013.02.005_bib15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clp.2013.02.005_bib16","first-page":"2803","article-title":"FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye","volume":"15","author":"Kim","year":"2009","journal-title":"Mol Vis"},{"key":"10.1016\/j.clp.2013.02.005_bib17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease","volume":"56","author":"Tolentino","year":"2011","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.clp.2013.02.005_bib18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan","volume":"155","author":"Wu","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clp.2013.02.005_bib19","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00417-010-1430-x","article-title":"Intrvitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage","volume":"248","author":"Nazari","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.clp.2013.02.005_bib20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/jop.2011.0060","article-title":"Intravitreal bevacizumab for retinopathy of prematurity","volume":"27","author":"Harder","year":"2011","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.clp.2013.02.005_bib21","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/eye.2012.111","article-title":"Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity","volume":"26","author":"Lee","year":"2012","journal-title":"Eye (Lond)"},{"issue":"Suppl 4","key":"10.1016\/j.clp.2013.02.005_bib22","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/IAE.0b013e3181ca1457","article-title":"Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin)","volume":"30","author":"Dorta","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.clp.2013.02.005_bib23","first-page":"113","article-title":"Intravitreal bevacizumab injection as a primary therapy for threshold disease (ROP) in Al Qassim region","volume":"1","author":"Salman","year":"2010","journal-title":"J\u00a0Clin Exp Ophthalmol"}],"container-title":["Clinics in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510813000304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510813000304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T20:58:27Z","timestamp":1539637107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095510813000304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0095510813000304"],"URL":"https:\/\/doi.org\/10.1016\/j.clp.2013.02.005","relation":{},"ISSN":["0095-5108"],"issn-type":[{"value":"0095-5108","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}